BioTissue, a regenerative biologics manufacturer, has signed a supplier contract with Vizient, a large healthcare performance improvement company in the United States.
Vizient, which works with 65% of US hospitals, will now have access to BioTissue’s allograft products, including Clarix 1K cryopreserved, ultra-thick human amniotic membrane allograft used as an adjunct for surgical, wound, and musculoskeletal applications. BioTissue reports that Clarix® 1K, a 361 HCT/P, can be used for tectonic support as a surgical covering, wrap, or barrier for patients.
A retrospective study found a median 89.5% improvement in pain and improved range of motion when Clarix Cord 1K was used as an interpositional graft during tarsal coalition surgery, with no infection or wound complications reported.
BioTissue also reports they’ve developed a proprietary cryopreservation process, called CryoTek®, which preserves the anti-inflammatory and regenerative properties of the amniotic tissue.
BioTissue is also conducting multiple clinical trials as it pursues Biologic License Applications (BLAs) for new products addressing unmet clinical needs. To date, clinicians have performed over 1 million human implants using BioTissue products, and there are more than 400 peer-reviewed publications supporting its platform technology.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
